NYCB’s stock downgraded to underperform at Raymond James on expectation of rising credit costs
Raymond James sees credit costs taking a bite out of earnings, while Moody’s hikes rating by one notch after $1.05B injection.
Raymond James sees credit costs taking a bite out of earnings, while Moody’s hikes rating by one notch after $1.05B injection.
